<a href="https://laohu8.com/S/TOVX">Theriva Biologics</a> Announces Corporate Reorganization, Cuts Workforce by 32% to Focus on Clinical Trials and Licensing Activities
**Theriva Biologics Announces Corporate Reorganization and Workforce Reduction** Theriva Biologics Inc. has announced a significant corporate reorganization aimed at focusing its efforts on business development, licensing activities, and advancing clinical trials for its lead product candidate, VCN-01. As part of the restructuring plan approved by the Board of Directors on September 28, 2025, the company implemented a workforce reduction of approximately 32%, affecting about seven employees. The move is expected to save Theriva around $2 million annually in compensation and benefits, with total restructuring charges estimated at $520,000 to be incurred in the fourth quarter of 2025. The company believes these changes will extend its cash runway into the second quarter of 2026 and better position it for upcoming regulatory meetings and planned clinical trials in pancreatic cancer and retinoblastoma.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theriva Biologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-096047), on October 02, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。